Job Description
Interested in helping to support the development of cutting edge AI products to empower cancer diagnostics and save lives? If so, we’d love to talk to you!
BioAI is an early-stage company that has developed the unique AI-powered PredictX platform that analyzes digital tumor tissue slides to predict genetic biomarkers. It uses the patterns that specific genetic mutations leave in the tissue architecture and morphology. Unlike standard molecular testing this is fast – hours instead of weeks-, cheaper, and an entire panel of different genetic biomarkers can be analyzed from a single piece of tumor tissue. Our current customers are pharmaceutical companies that need effective tests to identify cancer patients eligible for their precision therapies.
Come join BioAI and make a difference! We’re a fast-growing team with industry experts and innovators in artificial intelligence, translational science and diagnostics. Our technology has repeatedly outperformed competitors in bakeoffs with pharmaceutical companies.
As we begin to develop our own product portfolio and support pharma companies with the development of customized IVDs, we are excited to bring on a QA/QE Expert to ensure quality and quality procedures at BioAI.
Be prepared to thrive in an startup environment where culture and belonging are paramount and be a key part of developing it into an IVD company.
As the QA/QE Expert, you will be responsible for
Minimum Qualifications
Preferred Qualifications
BioAI believes that everyone has the ability to make an impact, and we are proud to be an equal opportunity employer committed to providing employment opportunity regardless of sex, race, creed, color, gender, religion, marital status, domestic partner status, age, national origin or ancestry, physical or mental disability, medical condition, sexual orientation, pregnancy, military or veteran status, citizenship status, and genetic information.
BioAI Health is a biotech company that uses AI to improve disease diagnosis and predict patient response to therapy. Its platform technology integrates complex data sets from translational studies and clinical trials. It has the capability to develop machine learning models on multi-omic data that can help predict patient response to therapy and drug resistance. The company was founded in 2020 and is based in Goffstown, New Hampshire.